Notably, the VEGF inhibitor Bevacizumab significantly suppresses the enrichment of ALDH+ CSCs and enhances the sensitivity of cervical carcinoma to cisplatin therapy [241]. This evidence concerns the gene VEGFA and cervical carcinoma.